| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.RES.75.1.144 |
| P698 | PubMed publication ID | 8013072 |
| P50 | author | R. Kent Hermsmeyer | Q101150519 |
| P2093 | author name string | S K Mishra | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 144-148 | |
| P577 | publication date | 1994-07-01 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Selective inhibition of T-type Ca2+ channels by Ro 40-5967 | |
| P478 | volume | 75 |
| Q38358958 | A potential reservoir of immature dopaminergic replacement neurons in the adult mammalian olfactory bulb. |
| Q74267656 | Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy |
| Q74787363 | Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris |
| Q73673622 | Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris |
| Q53943964 | Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. |
| Q54616735 | Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension. |
| Q46248730 | Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD. |
| Q77134020 | Antioxidant and cytoprotective activities of the calcium channel blocker mibefradil |
| Q41015853 | Antisense depletion of beta-subunits fails to affect T-type calcium channels properties in a neuroblastoma cell line. |
| Q37517378 | Assessment of the effectiveness and safety of Ethosuximide in the Treatment of non-Diabetic Peripheral Neuropathic Pain: EDONOT-protocol of a randomised, parallel, controlled, double-blinded and multicentre clinical trial |
| Q40932618 | Blockade of Ba2+ current through human alpha1E channels by two steroid analogs, (+)-ACN and (+)-ECN. |
| Q71637768 | Blockade of receptor-operated calcium channels by mibefradil (Ro 40-5967): effects on intracellular calcium and platelet aggregation |
| Q35853214 | Br-DIF-1 accelerates dimethyl sulphoxide-induced differentiation of P19CL6 embryonic carcinoma cells into cardiomyocytes |
| Q37055492 | Ca2+ and K+ channels of normal human adrenal zona fasciculata cells: properties and modulation by ACTH and AngII. |
| Q48314206 | Ca2+ channel antagonists and neuroprotection from cerebral ischemia |
| Q35566464 | Calcium antagonistic properties of the cyclooxygenase-2 inhibitor nimesulide in human myometrial myocytes |
| Q44189192 | Calcium channel blockade limits transcriptional, translational and functional up-regulation of the cardiac calpain system after myocardial infarction |
| Q31879451 | Calcium currents and arrhythmias: insights from molecular biology |
| Q27025564 | Calcium influx pathways in breast cancer: opportunities for pharmacological intervention |
| Q37054481 | Chronic hypoxia selectively enhances L- and T-type voltage-dependent Ca2+ channel activity in pulmonary artery by upregulating Cav1.2 and Cav3.2. |
| Q34342983 | Cirrhosis of the liver and receptor-mediated function in vascular smooth muscle |
| Q34756311 | Clinical pharmacokinetics of mibefradil |
| Q38997064 | Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. |
| Q84847621 | Closure of multiple types of K+ channels is necessary to induce changes in renal vascular resistance in vivo in rats |
| Q42546276 | Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD. Mibefradil Hypertension Study Group |
| Q42545413 | Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group |
| Q34988528 | Congenital heart block maternal sera autoantibodies target an extracellular epitope on the α1G T-type calcium channel in human fetal hearts |
| Q48666040 | Contrasting biophysical and pharmacological properties of T-type and R-type calcium channels. |
| Q46605055 | Contribution of different Ca²⁺ channels to the acrosome reaction-mediated initiation of sperm motility in the newt Cynops pyrrhogaster. |
| Q26849780 | Control of low-threshold exocytosis by T-type calcium channels |
| Q43262406 | Depolarization-induced calcium influx in rat mesenteric small arterioles is mediated exclusively via mibefradil-sensitive calcium channels |
| Q28369869 | Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels |
| Q37098011 | Development of a spontaneously active dorsal root ganglia assay using multiwell multielectrode arrays |
| Q51496112 | Differences in Ca2+ channels governing generation of miniature and evoked excitatory synaptic currents in spinal laminae I and II. |
| Q41653519 | Diversity of calcium antagonists |
| Q39162529 | Dopaminergic Neurones in the Main Olfactory Bulb: An Overview from an Electrophysiological Perspective. |
| Q73627062 | Effect of mibefradil on heart rate variability in patients with chronic heart failure |
| Q35350334 | Effects of T-type calcium channel blockers on renal function and aldosterone in patients with hypertension: a systematic review and meta-analysis |
| Q35029227 | Effects of anion channel antagonists in canine colonic myocytes: comparative pharmacology of Cl-, Ca2+ and K+ currents |
| Q36977351 | Effects of distension on airway inflammation and venular P-selectin expression |
| Q35042865 | Effects of mibefradil and nifedipine on arteriolar myogenic responsiveness and intracellular Ca(2+). |
| Q71377756 | Effects of mibefradil on intracellular Ca2+ release in cultured rat cardiac fibroblasts and human platelets |
| Q44217711 | Effects of mibefradil on uterine contractility |
| Q53949242 | Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise. |
| Q77498176 | Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats |
| Q72992813 | Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure |
| Q35739094 | Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. |
| Q26783154 | Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders |
| Q37049765 | Growth differentiation factor-15 promotes glutamate release in medial prefrontal cortex of mice through upregulation of T-type calcium channels |
| Q71606976 | Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction |
| Q43167290 | High affinity interaction of mibefradil with voltage-gated calcium and sodium channels. |
| Q35027993 | Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists |
| Q41653529 | Hypertension and pathologic cardiovascular remodeling: a potential therapeutic role for T-type calcium antagonists |
| Q35048422 | Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels |
| Q43260085 | Inadequate ischaemia-selectivity limits the antiarrhythmic efficacy of mibefradil during regional ischaemia and reperfusion in the rat isolated perfused heart. |
| Q73028222 | Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure |
| Q41108161 | Inhibition by mibefradil, a novel calcium channel antagonist, of Ca(2+)- and volume-activated Cl- channels in macrovascular endothelial cells. |
| Q62661282 | Inhibition of angiogenesis by blockers of volume-regulated anion channels |
| Q46604720 | Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect |
| Q77530970 | Inhibition of myogenic tone by mibefradil in rat cerebral arteries |
| Q34348626 | Interactions between calcium and reactive oxygen species in pulmonary arterial smooth muscle responses to hypoxia |
| Q35755697 | Intracellular calcium changes in rat aortic smooth muscle cells in response to fluid flow |
| Q43263625 | Involvement of T-type calcium channels in excitatory junction potentials in rat resistance mesenteric arteries. |
| Q33863915 | Ion channels and the control of blood pressure. |
| Q73739617 | Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem |
| Q35682302 | Low-voltage-activated ("T-Type") calcium channels in review |
| Q35048005 | Management of calcium channel antagonist overdose |
| Q73485500 | Metabolism of the calcium antagonist, mibefradil (POSICORTM, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man |
| Q30988574 | Methods of blood flow measurement in the arterial circulatory system |
| Q35028411 | Mibefradil (Ro 40-5967) inhibits several Ca2+ and K+ currents in human fusion-competent myoblasts. |
| Q57244982 | Mibefradil (Ro 40m5967) blocks multiple types of voltage-gated calcium channels in cultured rat spinal motoneurones |
| Q46225801 | Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists |
| Q79991429 | Mibefradil, a T-type Ca2+ channel blocker, protects against mesenteric ischemia-reperfusion-induced oxidative injury and histologic alterations in intestinal mucosa in rats |
| Q73739620 | Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics |
| Q74071707 | Mibefradil, an I(Ca,T) blocker, effectively blocks I(Ca,L) in rabbit sinus node cells |
| Q41634924 | Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris |
| Q41647645 | Mibefradil: a selective T-type calcium antagonist |
| Q35682306 | Modulation and pharmacology of low voltage-activated ("T-Type") calcium channels |
| Q35884606 | Modulation by extracellular ATP of L-type calcium channels in guinea-pig single sinoatrial nodal cell |
| Q41632466 | New developments in drug therapy of hypertension |
| Q35900990 | New mechanisms of pulmonary arterial hypertension: role of Ca²⁺ signaling. |
| Q30447500 | Nickel block of three cloned T-type calcium channels: low concentrations selectively block alpha1H. |
| Q41139770 | Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension |
| Q53247169 | No apparent role for T-type Ca²⁺ channels in renal autoregulation. |
| Q71198061 | Nonlinear pharmacokinetics of mibefradil in the dog |
| Q37360962 | Oxygen-induced constriction of rabbit ductus arteriosus occurs via inhibition of a 4-aminopyridine-, voltage-sensitive potassium channel |
| Q28373565 | Pharmacokinetic and pharmacodynamic aspects of concomitant mibefradil-digoxin therapy at therapeutic doses |
| Q41587071 | Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist |
| Q41198019 | Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist |
| Q41653526 | Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T-type calcium antagonists |
| Q40846301 | Potent inhibition of a recombinant low voltage-activated Ca(2+) channel by SB-209712. |
| Q43185405 | Potent vasodilatory with minor cardiodepressant actions of mibefradil in human cardiac tissue |
| Q71617066 | Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition |
| Q40930342 | Proportions of Ca2+ channel subtypes in chick or rat P2 fraction and NG108-15 cells using various Ca2+ blockers |
| Q41653540 | Rationale for the use of calcium antagonists in the treatment of silent myocardial ischemia |
| Q41653534 | Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality |
| Q37398441 | Role of T-type Ca Channels in the Spontaneous Phasic Contraction of Pregnant Rat Uterine Smooth Muscle. |
| Q43590325 | Role of membrane depolarization and T-type Ca2+ channels in angiotensin II and K+ stimulated aldosterone secretion |
| Q41653547 | Safety of calcium antagonists in patients with congestive heart failure |
| Q50936529 | Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. |
| Q40873132 | Selective T-type calcium channel block in thalamic neurons reveals channel redundancy and physiological impact of I(T)window |
| Q44233263 | Selectivity of different calcium antagonists on T- and L-type calcium currents in guinea-pig ventricular myocytes |
| Q33693617 | Systemic and ocular vascular roles of the antiglaucoma agents beta-adrenergic antagonists and Ca2+ entry blockers |
| Q30277635 | T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin |
| Q35044642 | T-channel-like pharmacological properties of high voltage-activated, nifedipine-insensitive Ca2+ currents in the rat terminal mesenteric artery. |
| Q43768749 | T-type Ca(2+) channels mediate neurotransmitter release in retinal bipolar cells. |
| Q39068338 | T-type Ca2+ channels and autoregulation of local blood flow |
| Q46907921 | T-type Ca2+ current as a trigger for Ca2+ release from the sarcoplasmic reticulum in guinea-pig ventricular myocytes |
| Q42021460 | T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats |
| Q35645713 | T-type calcium channel antagonists, mibefradil and NNC-55-0396 inhibit cell proliferation and induce cell apoptosis in leukemia cell lines |
| Q28306311 | T-type calcium channels blockers as new tools in cancer therapies |
| Q38960816 | T-type calcium channels in synaptic plasticity |
| Q73176224 | Targetting voltage-gated calcium channels in cardiovascular therapy |
| Q44630584 | The Influence of Calcium Channel Antagonists on Isolated Human Distal Radial Arteries |
| Q26781422 | The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential |
| Q71815308 | The binding interactions of Ro 40-5967 at the L-type Ca2+ channel in cardiac tissue |
| Q41653536 | The clinical significance of neurohormonal activation |
| Q53360878 | The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil). |
| Q73434055 | The effect of Portuguese Man-of-war (Physalia physalis) venom on calcium, sodium and potassium fluxes of cultured embryonic chick heart cells |
| Q38138513 | The many faces of T-type calcium channels |
| Q46403905 | The mechanism of increased postnatal heart rate and sinoatrial node pacemaker activity in mice |
| Q43281326 | Vasodilating dipeptide Trp-His can prevent atherosclerosis in apo E-deficient mice. |
| Q48567108 | WITHDRAWN: Differential involvement of L- and T-type Ca2+ channels, store-operated calcium channel (TRPC) and Rho-kinase signaling pathway(s) in PGF2α-induced contractions in myometrium of non-pregnant and pregnant buffaloes (Bubalus bubalis). |
Search more.